Enteromix cancer vaccine from Russia shows 100 per cent efficacy, awaits approval
Although the 10th Eastern Economic Forum in Vladivostok hosted over 100 discussions on economic and regional issues, the unveiling of the cancer vaccine, Enteromix, captured the spotlight.
A new Russian cancer vaccine has shown 100 per cent efficacy in preclinical trials, demonstrating both safety and strong tumour-fighting potential.
The breakthrough was announced at the 10th Eastern Economic Forum in Vladivostok, held from September 3 to 6. The event brought together more than 8,400 participants from 75 nations under the theme, “The Far East: Cooperation for Peace and Prosperity.”
More To Read
Although the forum hosted over 100 discussions on economic and regional issues, the unveiling of the cancer vaccine, Enteromix, captured the spotlight.
Developed by the Federal Medical and Biological Agency (FMBA), the mRNA-based vaccine is now ready for use pending official approval.
"The research spanned several years, with the last three dedicated to mandatory preclinical studies. The vaccine is now ready for use; we are awaiting official approval," FMBA head Veronica Skvortsova said during the announcement, according to multiple outlets.
Skvortsova explained that repeated administration of Enteromix during trials proved safe and produced remarkable results, including slowing tumour growth by 60–80 per cent.
Colorectal cancer
The vaccine will first target colorectal cancer, one of the leading causes of cancer-related deaths worldwide. Researchers are also developing versions for glioblastoma, a highly aggressive brain tumour, as well as certain melanomas, including ocular melanoma, which are already in advanced stages of study.
Unlike traditional vaccines, which train the immune system to fight viruses such as measles or chickenpox, cancer vaccines work by helping the body detect and destroy malignant cells.
Enteromix will be personalised for each patient according to their RNA (Ribonucleic acid), using four harmless viruses to attack tumours directly while boosting the body’s natural defences.
Medical experts highlight that therapeutic vaccines like Enteromix carry fewer risks of severe side effects compared to chemotherapy or radiation. In preclinical trials, the vaccine was well tolerated, underscoring its potential as a new class of cancer treatment.
While vaccines already exist for bladder and prostate cancers, and the HPV vaccine prevents several cancers before they develop, Enteromix represents a growing wave of therapies designed to directly combat cancer.
If approved, it could transform cancer treatment and provide new hope for patients worldwide.
Top Stories Today
